CytomX Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio2.53
Forward P/E16.30
P/S Ratio0.581.031.997.574.42
P/B Ratio-176.77-2.19-1.23-615.53-38.95
Price/FCF102.63
Price/OCF57.57
Enterprise Value Ratios
EV/Revenue1.840.11
EV/FCF2.48
Profitability & Returns
Return on Equity (ROE)-2.99%
Return on Assets (ROA)0.10%-0.02%-0.20%-0.21%-0.14%
Return on Capital Employed (ROCE)0.72%-0.14%-0.87%-0.44%-0.28%
Leverage & Solvency Ratios
Debt/Equity-20.58-0.29-0.21-47.22-3.20
Debt/EBITDA0.31
Debt/FCF8.43
Liquidity Ratios
Current Ratio1.251.171.553.984.76
Quick Ratio1.211.141.503.934.65
Efficiency Ratios
Asset Turnover0.860.440.180.110.20
Yield & Distribution Ratios
Earnings Yield0.40%-0.01%-0.94%-0.41%-0.21%
FCF Yield-1.07%-0.55%-1.06%-0.43%0.01%
Buyback Yield-0.15%-0.12%-0.02%-0.39%-0.02%